1. Pink Sheet
  2. >>Market Access

PBM Execs Stay On Message Amid Growing US Congressional Frustration At Hearing

 
• By Cathy Kelly

The House Oversight Committee held its third hearing on pharmacy benefit manager reforms in 14 months, but could not elicit an admission from executives that they are responsible for increasing drug prices.

House Oversight Committee PBM Hearing
PBM Executives Faced House Oversight Committee on 23 July. • Source: Screenshot of House Broadcast

Top executives at the three largest pharmacy benefit managers largely stuck to the script despite bipartisan skepticism and the growing frustration of the House Oversight and Accountability Committee with their testimony during a third hearing on industry reforms.

Key Takeaways

  • Leaders of the top three pharmacy benefit managers maintained they play a valuable role in lowering drug prices and denied putting costs before patient benefit during the House Oversight Committee's third PBM hearing.

The 23 July hearing was held with pressure building on PBMs from the Federal Trade Commission and state regulators. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 
• By Eliza Slawther

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By Vibha Sharma

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.

US CDC Vaccine Committee Revives Thimerosal Debate: A Portent Of Things To Come?

 
• By Bridget Silverman

The new Advisory Committee on Immunization Practices voted for new recommendations on the decades-old thimerosal safety issue and lays intellectual groundwork to revisit other past controversies and decisions.